Metabolic derangements in the gastrocnemius and the effect of Compound A therapy in a murine model of cancer cachexia

Journal of Cachexia, Sarcopenia and Muscle

Volumn 4, Issue 2, 2013, Pages 145-155

  Der Torossian, Hirak ^a,b   Wysong, Ashley ^c   Shadfar, Scott ^d   Willis, Monte S ^d   McDunn, Jonathan ^e   Couch, Marion E ^a,b  

^a UNIVERSITY OF VERMONT   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c STANFORD UNIVERSITY   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e METABOLON INC   (United States)

Author keywords

Cachexia; Cancer; Gastrocnemius; Metabolomics; Oxidative stress; Skeletal muscle; Warburg effect

Indexed keywords

2 HYDROXYBUTYRATE DEHYDROGENASE; 2 HYDROXYGLUTARIC ACID; 4 HYDROXYBUTYRIC ACID; ALANINE; ANSERINE; ARGININE; CARBOHYDRATE; CARNOSINE; COMPOUND A; FRUCTOSE 6 PHOSPHATE; GLUCOSE 6 PHOSPHATE; GLUTAMINE; GLUTATHIONE; GLYCEROL; GLYCEROL 3 PHOSPHATE ACYLTRANSFERASE; GLYCINE; HIPPURIC ACID; I KAPPA B KINASE INHIBITOR; INOSITOL 1 PHOSPHATASE; LYSINE; MALIC ACID; MANNITOL; MANNOSE; ORNITHINE; PEPTIDE; SERINE; TRICARBOXYLIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; URIDINE; XANTHOSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CACHEXIA; CELL PROLIFERATION; CONTROLLED STUDY; GASTROCNEMIUS MUSCLE; GLYCOLYSIS; MALE; METABOLOMICS; MOUSE; MUSCLE METABOLISM; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

EID: 84879197444     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1007/s13539-012-0101-7     Document Type: Article

References (46)

1. Morley JE, Thomas DR, Wilson MM. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr. 2006;83: 735-43.
2. Tisdale MJ. Cancer cachexia. Langenbecks Arch Surg. 2004;389: 299-305.
3. MacDonald N, Easson AM, Mazurak VC, Dunn GP, Baracos VE. Understanding and managing cancer cachexia. J Am Coll Surg. 2003;197: 143-61.
4. Bennani-Baiti N, Walsh D. What is cancer anorexia-cachexia syndrome? A historical perspective. J R Coll Physicians Edinb. 2009;39: 257-62.
5. Tisdale MJ. Cancer cachexia. Curr Opin Gastroenterol. 2010;26: 146-51.
6. Tan BH, Fearon KC. Cachexia: prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care. 2008;11: 400-7.
7. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer. 2002;2: 862-71.
8. Aulino P, Berardi E, Cardillo VM, Rizzuto E, Perniconi B, Ramina C, et al. Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse. BMC Cancer. 2010;10: 363.
9. Di Marco S, Cammas A, Lian XJ, Kovacs EN, Ma JF, Hall DT, et al. The translation inhibitor pateamine A prevents cachexia-induced muscle wasting in mice. Nat Commun. 2012;3: 896.
10. Bonetto A, Aydogdu T, Kunzevitzky N, Guttridge DC, Khuri S, Koniaris LG, et al. STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One. 2011;6: e22538.
11. Fujita J, Tsujinaka T, Yano M, Ebisui C, Saito H, Katsume A, et al. Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways. International journal of cancer Journal international du cancer. 1996;68: 637-43.
12. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol. 2009;27: 693-733.
13. van Gammeren D, Damrauer JS, Jackman RW, Kandarian SC. The IkappaB kinases IKKalpha and IKKbeta are necessary and sufficient for skeletal muscle atrophy. FASEB J. 2009;23: 362-70.
14. Wysong A, Couch M, Shadfar S, Li L, Rodriguez JE, Asher S, et al. NF-kappaB inhibition protects against tumor-induced cardiac atrophy in vivo. Am J Pathol. 2011;178: 1059-68.
15. Shadfar S, Couch ME, McKinney KA, Weinstein LJ, Yin X, Rodriguez JE, et al. Oral resveratrol therapy inhibits cancer-induced skeletal muscle and cardiac atrophy in vivo. Nutr Cancer. 2011;63: 749-62.
16. Ziegelbauer K, Gantner F, Lukacs NW, Berlin A, Fuchikami K, Niki T, et al. A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity. Br J Pharmacol. 2005;145: 178-92.
17. Tanaka K, Kiyosawa N, Honda K, Sharyo S, Ito K, Teranishi M, et al. Resistance to the skeletal muscle injury expressed by repeated treatment with compound A that has HMG-CoA reductase inhibitory activity. J Toxicol Sci. 2007;32: 9-18.
18. Diffee GM, Kalfas K, Al-Majid S, McCarthy DO. Altered expression of skeletal muscle myosin isoforms in cancer cachexia. Am J Physiol Cell Physiol. 2002;283: C1376-82.
19. O'Connell T, Ardeshirpour F, Asher S, Winnike J, Yin X, George J, et al. Metabolomic analysis of cancer cachexia reveals distinct lipid and glucose alterations. Metabolomics. 2008;4: 216-25.
20. Boudonck KJ, Mitchell MW, Nemet L, Keresztes L, Nyska A, Shinar D, et al. Discovery of metabolomics biomarkers for early detection of nephrotoxicity. Toxicol Pathol. 2009;37: 280-92.
21. Lawton KA, Berger A, Mitchell M, Milgram KE, Evans AM, Guo L, et al. Analysis of the adult human plasma metabolome. Pharmacogenomics. 2008;9: 383-97.
22. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E. Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem. 2009;81: 6656-67.
23. Sha W, da Costa KA, Fischer LM, Milburn MV, Lawton KA, Berger A, et al. Metabolomic profiling can predict which humans will develop liver dysfunction when deprived of dietary choline. FASEB J. 2010;24: 2962-75.
24. Dehaven CD, Evans AM, Dai H, Lawton KA. Organization of GC/MS and LC/MS metabolomics data into chemical libraries. J Cheminformatics. 2010;2: 9.
25. Gall WE, Beebe K, Lawton KA, Adam KP, Mitchell MW, Nakhle PJ, et al. Alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS One. 2010;5: e10883.
26. Mastrocola R, Reffo P, Penna F, Tomasinelli CE, Boccuzzi G, Baccino FM, et al. Muscle wasting in diabetic and in tumor-bearing rats: role of oxidative stress. Free Radic Biol Med. 2008;44: 584-93.
27. Moylan JS, Reid MB. Oxidative stress, chronic disease, and muscle wasting. Muscle Nerve. 2007;35: 411-29.
28. Gomes-Marcondes MC, Tisdale MJ. Induction of protein catabolism and the ubiquitin-proteasome pathway by mild oxidative stress. Cancer Lett. 2002;180: 69-74.
29. Barreiro E, de la Puente B, Busquets S, Lopez-Soriano FJ, Gea J, Argiles JM. Both oxidative and nitrosative stress are associated with muscle wasting in tumour-bearing rats. FEBS Lett. 2005;579: 1646-52.
30. Murr C, Fuith LC, Widner B, Wirleitner B, Baier-Bitterlich G, Fuchs D. Increased neopterin concentrations in patients with cancer: indicator of oxidative stress? Anticancer Res. 1999;19: 1721-8.
31. Shum AM, Mahendradatta T, Taylor RJ, Painter AB, Moore MM, Tsoli M, et al. Disruption of MEF2C signaling and loss of sarcomeric and mitochondrial integrity in cancer-induced skeletal muscle wasting. Aging. 2012;4: 133-43.
32. Martinez-Outschoorn UE, Pestell RG, Howell A, Tykocinski ML, Nagajyothi F, Machado FS, et al. Energy transfer in "parasitic" cancer metabolism: mitochondria are the powerhouse and Achilles' heel of tumor cells. Cell Cycle. 2011;10: 4208-16.
33. Ko YH, Lin Z, Flomenberg N, Pestell RG, Howell A, Sotgia F, et al. Glutamine fuels a vicious cycle of autophagy in the tumor stroma and oxidative mitochondrial metabolism in epithelial cancer cells: implications for preventing chemotherapy resistance. Cancer Biol Ther. 2011;12: 1085-97.
34. Reid MB, Li YP. Cytokines and oxidative signalling in skeletal muscle. Acta Physiol Scand. 2001;171: 225-32.
35. van Wessel T, de Haan A, van der Laarse WJ, Jaspers RT. The muscle fiber type-fiber size paradox: hypertrophy or oxidative metabolism? Eur J Appl Physiol. 2010;110: 665-94.
36. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (New York, NY). 2009;324: 1029-33.
37. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 2008;134: 703-7.
38. Serrano AL, Baeza-Raja B, Perdiguero E, Jardi M, Munoz-Canoves P. Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. Cell Metab. 2008;7: 33-44.
39. Lopez-Lazaro M. The Warburg effect: why and how do cancer cells activate glycolysis in the presence of oxygen? Anti Cancer Agents Med Chem. 2008;8: 305-12.
40. Tretter L, Adam-Vizi V. Alpha-ketoglutarate dehydrogenase: a target and generator of oxidative stress. Philos Trans R Soc Lond B Biol Sci. 2005;360: 2335-45.
41. Tretter L, Adam-Vizi V. Inhibition of Krebs cycle enzymes by hydrogen peroxide: a key role of [alpha]-ketoglutarate dehydrogenase in limiting NADH production under oxidative stress. J Neurosci. 2000;20: 8972-9.
42. Gupta SC, Kim JH, Kannappan R, Reuter S, Dougherty PM, Aggarwal BB. Role of nuclear factor kappaB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents. Exp Biol Med (Maywood). 2011;236: 658-71.
43. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277: 16639-47.
44. Willis MS, Schisler JC, Patterson C. Appetite for destruction: E3 ubiquitin-ligase protection in cardiac disease. Future Cardiol. 2008;4: 65-75.
45. Aragno M, Mastrocola R, Brignardello E, Catalano M, Robino G, Manti R, et al. Dehydroepiandrosterone modulates nuclear factor-kappaB activation in hippocampus of diabetic rats. Endocrinology. 2002;143: 3250-8.
46. Rhoads MG, Kandarian SC, Pacelli F, Doglietto GB, Bossola M. Expression of NF-kappaB and IkappaB proteins in skeletal muscle of gastric cancer patients. Eur J Cancer. 2010;46: 191-7.